July 15, 2025

Supplementary Figure S3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: The study presents the first-in-class cdk2/4/6 inhibitor PF-06873600 in relation to breast cancer.
KEY EVIDENCE: Median ctDNA change alongside progression-free survival (PFS) was assessed in treated patients.
APPROACH: This phase I/IIa study evaluated the drug alone and in combination with endocrine therapy.
SIGNIFICANCE: Findings suggest the potential of PF-06873600 to enhance treatment strategies for breast cancer.

No abstract yet

We only have this paper's title and publication details.

No takes yet. Share an insight, caveat, or question.

Phase I/IIa study shows median ctDNA change and PFS in breast cancer patients, indicating potential benefits of treatment with endocrine therapy.

Yap et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase I/IIa study shows median ctDNA change and PFS in breast cancer patients, indicating potential benefits of treatment with endocrine therapy.